Q-901 is under clinical development by Qurient and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Q-901’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Q-901 is under development for the treatment of solid tumor, castration resistant prostate cancer, high grade serous ovarian cancer, metastatic ovarian cancer, hormone refractory (castration resistant, androgen-independent) prostate cancer, HER2- breast cancer, endometrial cancer, colorectal cancer, small-cell lung cancer, and pancreatic cancer. It is administered through oral and intravenous route. The drug candidate is Pyrazolo-triazine derivatives and targets cyclin-dependent kinase 7 (CDK7). Regulation of transcription of Mcl-1 (a key neutrophil survival protein) and involvement in pivotal inflammatory signaling via NF-kB are functions of CDKs-7. It was also under development for the treatment of inflammation and viral infections including cytomegalovirus infections.
Qurient is a biotechnology company. It develops drugs for unmet medical needs of atopic diseases and cancer. The company offers pipeline products that include Q301, a topical leukotriene inhibitor for the treatment of atopic dermatitis; Telacebec (Q203), a Cyt bc1 Inhibitor for combating mycobacterium associated tuberculosis infection; and Q702, an Axl/Mer/CSF1R triple kinase inhibitor for the treatment of drug resistant non-small cell lung cancer and other cancer types. Qurient in-licensed Q702 from Max Planck Innovation and Lead Discovery Center. It is also advancing its pre-clinical pipeline that includes a topical 5-lipoxygenase inhibitor to treat allergic and atopic diseases; and selective CDK7 inhibitors to treat cancer. Qurient is headquartered in Seongnam, Gyeonggi, South Korea.
For a complete picture of Q-901’s drug-specific PTSR and LoA scores, buy the report here.